Subject: Specialty Quantity Limit Ilumya 2543-H P2026

Drug

ILUMYA  (tildrakizumab-asmn)

Policy:

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member’s plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

Covered Quantities

Coverage up to the exception limit may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

Medication	Standard Limit	Exception Limit
Ilumya (tildrakizumab-asmn) 100 mg/mL single-dose prefilled syringe	1 syringe per 84 days	2 syringes per 28 days

FDA-recommended Dosing

100 mg at weeks 0, 4, and every 12 weeks thereafter

Place of Service:

Outpatient

The above policy is based on the following references:

1.      Ilumya [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; December 2025.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

June 14, 2026